The prognosis for patients with secondary AML, primary resistant AML or ALL and early (Ͻ12 months) relapse of acute leukaemia remains extremely poor with conventional chemotherapy. As part of a strategy to improve the outcome for these patients we have treated 22 consecutive patients (18 AML, four ALL, median age 35 years) with either primary resistant disease (n = 3), early relapsed leukaemia (n = 12) or secondary AML (n = 7, four RAEBt, two antecedant ALL and one antecedant Hodgkin's disease) with 'FLAG' induction chemotherapy with the aim of proceeding to early allogeneic transplantation either from sibling or unrelated donors. Eighteen patients achieved CR after one course of FLAG, including five patients who had documented p-glycoprotein-induced multidrug resistance and 10 patients with adverse cytogenetic abnormalities. Eight patients were consolidated with a second course of FLAG prior to transplantation and so far 16 patients have undergone allogeneic transplantation, 10 from unrelated donors and six from sibling donors (one mismatched). By the time of transplant three patients had progressed and were in early relapse and all have relapsed post BMT. Of the remaining 13 patients transplanted in remission, nine remain in CCR at a range of 4-26 months, three have died of transplant-related complications (18%) and one patient has relapsed. We conclude that the use of FLAG induction therapy followed by early allogeneic transplantation from either a sibling or unrelated donor can be an effective strategy for the treatment of this difficult group of young patients with poor risk acute leukaemia and appears to be associated with a low procedure-related risk.
Introduction
The prognosis for patients with secondary AML, primary refractory AML or ALL and early relapse of acute leukaemia remains extremely poor with conventional chemotherapy. 1 The only curative option for the majority of these patients is with allogeneic stem cell transplantation from a suitable HLAmatched sibling or unrelated donor. However, even when such a donor can be identified, a successful outcome from transplantation is largely dependent on the disease status at the time of transplantation, 2 with those patients transplanted in CR or with a minimal number of blasts in the marrow, having a significantly better outcome than those transplanted in relapse. Thus, one of the major challenges in treating this group of patients is to find a chemotherapeutic regimen which has minimal toxicity and yet is capable of inducing a high rate of complete remissions durable enough to allow allogeneic transplantation to be undertaken.
It is known that high-dose cytarabine (Ara-C), which is converted to its active form Ara-CTP within cells, is one of the most effective agents in the treatment of MDS and AML, 3 perhaps because it cannot be effluxed by multidrug resistance membrane pumps which are often operative within the leuCorrespondence: NH Russell, Department of Haematology, City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; Fax: 0115 962 7742 Received 5 October 1998; accepted 27 January 1999 kaemic blasts of these patients. Recent evidence suggests that the purine analogue fludarabine can act synergistically to increase the rate of accumulation of Ara-CTP in leukaemic blasts when scheduled beforehand, 4 resulting in enhanced killing of these cells. 5 These data have resulted in the development of novel chemotherapeutic regimens combining these two drugs, eg FLAG, in which the addition of G-CSF is hoped to further sensitise the leukaemic blasts to Ara-C 6, 7 and shorten the period of neutropenia, and FLAG-Ida, which includes the addition of the anthracycline idarubicin.
Considerable experience with FLAG and its derivatives has now been reported and suggests a reproducibly high CR rate of over 50% in all series with low toxicity. [8] [9] [10] [11] [12] [13] However, remission duration appears to be short, with a median of about 3 months in most series in which it has been studied, 8, 12 suggesting that additional therapy is required to achieve longterm survival in these patients. Our approach has therefore been to use the FLAG regimen or its derivative FLAG-Ida to achieve complete remission in these difficult patients followed by early allogeneic transplantation from either a sibling or an unrelated donor if no suitable sibling donor was available. Here, we report on the outcome of this strategy in 22 patients who have been entered into this study, of whom 16 have proceeded to allogeneic transplantation.
Patients and methods

Patients
Between January 1995 and March 1998 we treated 22 patients (median age 32 years, range 15-55 years; 12 males and 10 females) with the FLAG/FLAG-Ida chemotherapy regimens with the intention of proceeding to early allogeneic transplantation (Table 1) . Six of these patients had a secondary AML (three previous MDS; two previous ALL and one previous Hodgkin's disease); three patients had primary refractory AML; eight patients had early (Ͻ12 months relapse of AML), one had relapsed at 20 months and four patients had early relapse of ALL. One of the patients with refractory AML had Noonan's syndrome and had been thrombocytopenic for 18 years prior to the development of AML. All patients had bone marrow findings consistent with acute leukaemia at entry to the study and all had cytogenetic evaluation performed before commencing chemotherapy. Twelve patients were found to have standard risk cytogenetics whereas 10 patients had an adverse karyotype. We were able to identify a suitable potential sibling or unrelated donor in all but one patient (patient 10) during the first cycle of FLAG/FLAG-Ida chemotherapy.
FLAG/FLAG-Ida chemotherapy
Fludarabine 30 mg/m 2 was administered by i.v. infusion for 5 consecutive days and 4 h after commencing the fludarabine, cytarabine 2 g/m 2 was infused over 4 h. Subcutaneous G-CSF (filgrastim) at a standard dose of 300 g commenced 1 day prior to the administration of chemotherapy and was continued until day +5. G-CSF was then restarted 7 days after the completion of the chemotherapy and continued until neutrophil regeneration occurred (neutrophils Ͼ0.5 × 10 9 /l). Four patients also received idarubicin 8 mg/m 2 i.v. (FLAG-Ida) for the first 3 days of the chemotherapy (see Table 2 ). Eight patients received a second consolidating course of FLAG chemotherapy depending on their response to the initial course and the scheduling of allogeneic transplantation.
All patients received prophylactic antibiotics according to local protocols which included cotrimoxazole (960 mg twice a day twice weekly) for PCP prophylaxis and intravenous antibiotics were administered at the onset of pyrexia. All patients were scheduled to receive irradiated blood products for prevention of transfusion-related graft-versus-host disease. A bone marrow aspirate was performed following neutrophil regeneration to assess disease response. CR was defined as evidence of normal haemopoiesis with Ͻ5% blasts present and normal peripheral blood counts (platelets Ͼ100 × 10 9 /l and neutrophils Ͼ1 × 10 9 /l). PR was defined in patients who had evidence of trilineage myelodysplasia with Ͻ5% blasts ('dysplastic remission'). Patients were considered to have primary refractory disease if there was less than a 50% reduction in blasts following the first course of chemotherapy.
Allogeneic stem cell transplantation
Allogeneic transplantation was carried out using standard conditioning protocols consisting of cyclophosphamide 60 mg/kg × 2 days and TBI 12 Gy in six fractions for those patients with fully matched sibling donors whilst those undergoing matched unrelated donor transplantation or mismatched sibling transplants received TBI at a dose of 14.4 Gy in six fractions and additional ATG therapy (IMTIX, Maidenhead, UK) 150 mg from day-5 to day −1. Of the six patients undergoing sibling transplants, five received grafts from fully HLA-matched donors and in one case from a two antigen mismatched sibling donor. The source of stem cells used for the sibling allografts was G-CSF-mobilised peripheral blood stem cells in four patients and bone marrow in the remaining two patients. All patients undergoing unrelated donor transplantation received unmanipulated bone marrow grafts. Eight patients received grafts from fully HLA-matched volunteer donors and in three cases the donor was mismatched at a single HLA-A or B locus (see Table 2 ) using high resolution molecular techniques. GVHD prophylaxis was with CsA (commencing i.v. on day −1) and MTX (15 mg/m 2 on day +1 and 10 mg/m 2 on days +3, +6 and +11. CsA levels were maintained within a target range of 95-205 ng/ml for the patients with matched sibling donors and between 200 and 300 ng/ml in those with unrelated or mismatched donors.
Multidrug resistance studies
A detailed analysis of the multidrug resistance phenotype of the leukaemic blasts was performed where possible using established flow cytometric methods.
14 Briefly, blast cell populations were identified by gating on CD45 low positive events 15 and then expression of p-glycoprotein (p-gp) was 788 analysed by immunofluorescence using the mrk-16 antibody.
The presence of functional efflux was determined by demonstration of cyclosporine-induced modulation of rhodamine 123 accumulation. 14 Expression of the lung resistance protein (LRP) and multidrug resistance-associated protein (MRP) was detected using the LRP-56 and the MRP-r1 antibodies, respectively (Monosan, Uden, The Netherlands).
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Results
Response to FLAG chemotherapy
The response to the FLAG containing remission induction regimens is shown in Table 2 . Overall 18 out of 22 patients achieved CR following one course of therapy although eight showed persisting myelodysplastic features with Ͻ5% blasts in the marrow. Of the four patients who failed to respond to the FLAG regimens, two had relapsed ALL, one had a therapyrelated AML following previous treatment for acute lymphoblastic leukaemia and one was a patient with refractory AML. Attainment of remission appeared to be in part related to karyotype, since nine out of nine patients with standard risk cytogenetics achieved CR compared to eight out of 11 patients with poor risk cytogenetics, although this did not reach significance (P = 0.17) (see Table 2 ). The FLAG regimens were well tolerated, but one patient died despite achieving remission of probable transfusion-related graft-versus-host disease before reaching transplantation. No clear difference was noted in the response rate between those patients receiving the standard FLAG protocol and those four patients who additionally received idarubicin (FLAG-Ida) although haematological recovery appeared to be slower (data not shown) and therefore we have chosen to use the standard FLAG protocol in the more recently treated patients. Eight out of the 18 responding patients were consolidated with a further course of FLAG chemotherapy whilst awaiting allogeneic transplantation and so far 16 patients have been transplanted. Three patients were in early relapse at the time of transplant despite two of these patients receiving FLAG consolidation. We have deferred transplantation in one other patient with a secondary AML (patient 14) who was aged 55 years and had a two antigen mismatched sibling donor due to poor clinical condition. Interestingly, he remains in CCR at 12 months post-treatment with evidence of mild dysplastic features only.
Multidrug resistance studies
A detailed multidrug resistance (MDR) profile was determined for the leukaemic blasts of six patients prior to commencing the FLAG regimen (three with relapsed AML and three with refractory AML) and one patient who relapsed after an unrelated donor transplant and who went on to receive a further course of FLAG-Ida (Table 3) . It was not possible to study more patients since several patients presented to other hospitals and no material was available, and others had an insufficient percentage of blasts for meaningful analysis. One of the patients (patient 5) was studied following relapse after unrelated donor transplantation and prior to receiving a further course of FLAG-Ida as reinduction chemotherapy. This patient had previously achieved CR following the standard FLAG protocol but no material was available for comparison prior to this initial course of treatment.
Five patients were found to express p-gp and in all these cases this was associated with functional efflux as shown by cyclosporine modulation of rhodamine 123 accumulation. The patient who was studied following relapse after unrelated donor transplantation showed evidence of functional efflux in the absence of p-gp expression, suggesting a non-p-gp-depen- dent mechanism. Three of the patients with functional efflux also had elevated MRP expression, whilst in one patient, elevated expression of LRP was the only abnormality found. Following FLAG/FLAG-Ida chemotherapy, all five patients showing an efflux-positive/p-gp-positive phenotype achieved CR, whereas of the two failures one was the patient with an effluxpositive, p-gp-negative phenotype in whom a non-p-gpdependent mechanism was suspected and the other was efflux negative and p-gp negative but strongly LRP positive. No apparent relationship between MRP expression and the response to FLAG was noted although the numbers involved are small.
Outcome of transplantation
Sixteen of the 18 patients who achieved a CR post-FLAG have undergone allogeneic transplantation, 10 from unrelated donors and six from sibling donors (one mismatched). Three deaths occurred from transplant-related toxicity (see Table 2 ), including one early death from cardiac failure on day +6, in a patient known to have significant anthracycline-induced cardiomyopathy pre-transplant. The other two deaths were from cyclosporine-induced TTP occurring on day +21 and CMV pneumonitis on day +60. There have been no late transplant-related deaths. The incidence of acute GVHD was low, with nine out of 14 evaluable patients having no GVHD, four patients with grade 1 GVHD and only one patient having grade 2 GVHD. Three patients have gone on to develop limited chronic GVHD.
Three patients were in early relapse post-FLAG at the time of transplantation and all these patients relapsed within 6 months of the transplant. Of the 13 patients transplanted in remission there has only been one relapse occurring exactly 12 months post-transplant (patient 5) although the follow-up time remains short for some patients (range 4-24 months). Disease-free survival for the transplanted patients is shown in Figure 1 and is 42% at 2 years (95% CI = 16-68%) and is 56% (95% CI = 26.3-85.7%) for those patients transplanted in remission. The disease-free survival for all patients on an
Figure 1
Kaplan-Meier plot showing the disease-free survival of poor risk acute leukaemia patients proceeding to allogeneic transplantation following FLAG induction chemotherapy.
intention to treat basis is 35% (95% CI = 14-56%) (Figure 2) . The outcome appears superior for recipients of sibling transplants with five out of six patients alive and in CR compared to four out of 10 patients receiving transplants from unrelated donors. The outcome following transplantation did not appear to be affected by cytogenetics with a comparable outcome in the group with standard risk cytogenetics (five out of 10 in CCR) compared to four out of 10 survivors in the group with adverse cytogenetics.
Discussion
The prognosis for patients with refractory, early relapsed and secondary or therapy-related leukaemias remains poor in most series reported. Many such patients fail to achieve CR with conventional chemotherapeutic regimens and in those that do
Figure 2
Kaplan-Meier plot showing the disease-free survival of all poor risk acute leukaemia patients from the start of the FLAG regimen.
respond, remission duration is usually short with many patients relapsing early. Indeed, evidence from the MD Anderson Cancer Centre suggests that patients who fail to remit with conventional chemotherapy or who relapse within 2 years are incurable with standard regimens. 1 Several recent studies have shown that a high CR rate of 50-80%, can be reproducibly achieved using the FLAG/FLAGIda regimens in these poor risk AML patients. [8] [9] [10] [11] [12] [13] These results compare favourably with the use of other Ara-C containing reinduction regimens which have reported CR rates of 43% and 47% in similar groups of high risk patients. 16, 17 However, the response rate to FLAG/FLAG-Ida may be reduced in elderly patients Ͼ50 years and in those with unfavourable chromosomal abnormalities, 12,13 particularly monosomy 7.
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One drawback to using this treatment approach is that most of these studies have shown that the remissions induced by the FLAG/FLAG-Ida regimens have been of short duration, averaging 3-9 months. 9, [11] [12] [13] 18 In view of these data we have adopted a strategy for poor risk AML patients of reinduction with FLAG/FLAG-Ida chemotherapy followed by early allogeneic transplantation from HLA-matched sibling or unrelated donors. In addition, since the purine analogue, fludarabine, is also known to be effective in the treatment of patients with chronic lymphoproliferative disorders, inducing CR in up to 70% of patients with CLL, and good PR rates in other low grade non-Hodgkin's lymphomas, 19 we have also evaluated the use of this protocol in four patients with early relapse of ALL. The efficacy of FLAG-based regimens in the setting of early relapsed ALL is not yet proven, although previous reports have shown responses in some patients 10, 20, 21 and it is known that conventional chemotherapy protocols often give disappointing results in this group of patients.
In this study, the overall CR rate following the FLAG regimens was 18 out of 22 patients (82%) with no apparent advantage seen in the four patients who received additional idarubicin (FLAG-Ida). Of the four patients who failed to respond, two had relapsed ALL, one had a therapy-related leukaemia following previous treatment for ALL and one had refractory AML. Thus the CR rate for the patients with AML was 16 out of 18 (88%) compared to 50% in the ALL patients, although the numbers in this group were very small (two out of four). It is also noteworthy that a third patient with relapsed ALL only achieved a transient CR following FLAG, rapidly relapsing within weeks of treatment while awaiting unrelated donor transplantation. Thus only one patient with relapsed ALL has had a sustainable remission using this approach and remains in CCR at 18 months post transplant. It is of interest to note that this patient's blasts co-expressed myeloid antigens, since in a previous study of FLAG in ALL, attainment of CR was significantly related to the coexpression of myeloid antigens. 21 There was no obvious impact of adverse cytogenetics in this study with comparative CR rates in patients with both standard risk (nine out of nine) and unfavourable (eight out of 11) karyotypes. A detailed MDR phenotype of the leukaemic blasts was available in six patients with relapsed/refractory AML prior to the start of FLAG/FLAG-Ida treatment. One further patient (patient 5) had MDR analysis performed following relapse after an unrelated donor transplant. All the patients studied were found to express an MDR phenotype. Five of the seven patients studied had high level expression of p-gp associated with functional efflux demonstrated by cyclosporine modulation of rhodamine 123 accumulation, and all these patients achieved CR following FLAG. The incidence of elevated p-gp expression was higher in this group of poor risk AML patients compared with that seen in an unselected group of AML patients studied in our laboratory in whom p-gp positivity was demonstrated in 26 out of 50 patients (data not shown). Although the numbers are small, this is of interest since it is known that p-gp expression is a poor prognostic factor in AML and has been associated with a low CR rate of 30-60% in response to conventional chemotherapy regimens in most series reported. [22] [23] [24] There are little data available regarding the response to FLAG in patients known to express p-gp although one previous study reported eight out of 12 such patients achieving CR following FLAG. 18 Of the two patients who failed to remit, one had high level expression of LRP and the other patient, studied following relapse after unrelated donor transplantation showed evidence of functional efflux despite having no evidence of increased p-gp expression, suggesting a non-p-gp-dependent efflux mechanism. Since this patient was not studied prior to the first course of FLAG chemotherapy it is unclear whether this phenotype was present at that time or whether it had been induced following exposure to the FLAG regimen. No clear relationship between MRP and the achievement of CR following FLAG was noted. Although larger numbers are required, these preliminary results suggest that the FLAG regimens may be able to overcome MDR due to p-gp-dependent mechanisms but not MDR due to LRP or other p-gp-independent mechanisms.
Eight patients had marked dysplastic features following FLAG induction chemotherapy but this did not appear to be associated with the presence of adverse cytogenetic abnormalities. Two of these patients were found to be in early relapse prior to transplantation and subsequently relapsed post-transplant, whereas those 'dysplastic remission' patients transplanted in CR have not had a higher risk of relapse, suggesting that in these patients early scheduling of the transplant is critical.
Having achieved CR our strategy was to proceed to allogeneic transplantation as soon as possible with the rationale of trying to reduce transplant-related toxicity and mortality in this heavily treated group of patients. Unsurprisingly therefore, most patients in this study received transplants from unrelated donors and the time required to identify a donor and proceed to BMT was longer in these patients, resulting in a second consolidation course of FLAG chemotherapy being given in five out of 10 cases. Despite this the overall median time from entry into the study (initiation of the first course of FLAG/FLAG-Ida) to BMT was short at 8 weeks (range 6-18 weeks), and we were able to identify a suitable donor for all the patients who achieved a CR in response to FLAG and were eligible to proceed to allogeneic transplantation.
In total, 16 out of 18 eligible patients have proceeded to allogeneic transplantation, 10 from unrelated and six from sibling donors. Three out of 16 patients (18%) have died of transplant-related complications all following unrelated donor BMT, and four have relapsed, three of whom were in early relapse at the time of transplant. Nine patients remain in CCR at 4-26 months post-transplant and the disease-free survival is 42% at 2 years for the transplanted patients which compares favourably with EBMT data in this group of poor risk patients. 25 The outcome appears superior for recipients of sibling transplantation with five out of six patients surviving in CCR with no transplant-related deaths compared to four out of 10 patients in CCR following unrelated donor transplantation. However, these results of unrelated donor BMT are comparable to those recently reported from Seattle, 26 particularly for patients transplanted in remission. In addition, younger patients appeared to have a superior outcome, since of the nine patients in CCR only two are aged over 40 years. The incidence of GVHD was low in this series, including those patients who received unrelated donor grafts and we are currently reducing the amount of post-transplant immunosuppression in this group of patients to maximise graft-versusleukaemia effects.
In summary, we conclude that the use of the FLAG/FLAGIda chemotherapy protocols are effective in the treatment of poor risk AML, even for those with confirmed multidrug resistance, but may be less effective in the management of ALL, although a larger number of patients is required to confirm this. Furthermore, for patients in remission post-FLAG early allogeneic transplantation from either matched or mismatched sibling or unrelated donors appears to be a promising strategy with low toxicity for this difficult group of patients.
